Lopinavir [192725-17-0]

Referencia HY-14588-250mg

embalaje : 250mg

Marca : MedChemExpress

Contact local distributor :


Teléfono : +1 850 650 7790

Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM.

Para uso exclusivo en investigación. No vendemos a pacientes.

Lopinavir Estructura química

Lopinavir Estructura química

No. CAS : 192725-17-0

This product is a controlled substance and not for sale in your territory.

Based on 15 publication(s) in Google Scholar

Other Forms of Lopinavir:

  • (rel)-Lopinavir-d8 Obtener un presupuesto
  • Lopinavir-d8 Obtener un presupuesto
  • Lopinavir-d7 Obtener un presupuesto
  • Lopinavir (Standard) Obtener un presupuesto

    Lopinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Nov 10;105463.  [Abstract]

    Lopinavir (LPV) (0, 1, 5, 10, 20 μM; 24 h) inhibits autophagy in U87 cells in a dose-dependent manner.

    Lopinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Nov 10;105463.  [Abstract]

    Lopinavir (LPV) (1, 5, 10, 20, 50 µM; 12, 24, 36, 48 h) inhibits the growth of U87 cells.

    Ver todos los productos específicos de isoformas HIV:

    Ver todas las isoformas
    HIV HIV-1 HIV-2
    Descripciòn

    Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].

    IC50 & Target

    HIV-1

     

    In Vitro

    HIV-1 protease is an essential enzyme for production of mature, infective virus[1].
    Lopinavir potently inhibits wild-type and mutant HIV protease (Ki= 1.3 to 3.6 pM), blocks the replication HIV type 1 (EC50=0.006 to 0.017 μM), and maintains high potency against mutant HIV selected by Ritonavir in vivo (EC50=≤0.06 μM)[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Coadministration with low-dose Ritonavir significantly improves the pharmacokinetic properties and hence the activity of Lopinavir against HIV-1 protease[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ensayo clínico
    Peso molecular

    628.80

    Fòrmula

    C37H48N4O5

    No. CAS

    192725-17-0

    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CC1=C(OCC(N[C@@H](CC2=CC=CC=C2)[C@@H](O)C[C@H](CC3=CC=CC=C3)NC([C@H](C(C)C)N4C(NCCC4)=O)=O)=O)C(C)=CC=C1

    Envío

    Room temperature in continental US; may vary elsewhere.

    Almacenamiento
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvente y solubilidad
    In Vitro: 

    DMSO : 250 mg/mL (397.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.5903 mL 7.9517 mL 15.9033 mL
    5 mM 0.3181 mL 1.5903 mL 3.1807 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Calculadora de molaridad

    • Calculadora de dilución

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 25 mg/mL (39.76 mM); Clear solution

      This protocol yields a clear solution of ≥ 25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (250.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    • Protocol 2

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (3.31 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  Corn Oil

      Solubility: 20 mg/mL (31.81 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Pureza y Documentación

    Purity: 99.87%

    Referencias
    • [1]. Cvetkovic RS, et al. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63(8):769-802.  [Content Brief]

      [2]. Sham HL, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42(12):3218-3224.  [Content Brief]

      [3]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.5903 mL 7.9517 mL 15.9033 mL 39.7583 mL
    5 mM 0.3181 mL 1.5903 mL 3.1807 mL 7.9517 mL
    10 mM 0.1590 mL 0.7952 mL 1.5903 mL 3.9758 mL
    15 mM 0.1060 mL 0.5301 mL 1.0602 mL 2.6506 mL
    20 mM 0.0795 mL 0.3976 mL 0.7952 mL 1.9879 mL
    25 mM 0.0636 mL 0.3181 mL 0.6361 mL 1.5903 mL
    30 mM 0.0530 mL 0.2651 mL 0.5301 mL 1.3253 mL
    40 mM 0.0398 mL 0.1988 mL 0.3976 mL 0.9940 mL
    50 mM 0.0318 mL 0.1590 mL 0.3181 mL 0.7952 mL
    60 mM 0.0265 mL 0.1325 mL 0.2651 mL 0.6626 mL
    80 mM 0.0199 mL 0.0994 mL 0.1988 mL 0.4970 mL
    100 mM 0.0159 mL 0.0795 mL 0.1590 mL 0.3976 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Lopinavir Related Classifications

    Help & FAQs

    Keywords:

    Lopinavir192725-17-0ABT-378ABT378ABT 378HIVHIV ProteaseSARS-CoVHuman immunodeficiency virusSARS coronaviruswild-typemutantcoadministrationreplicationinfectionInhibitorinhibitorinhibit

    Usted podría estar interesado también en los siguientes productos:



    Referencia
    Descripción
    Cond.
    Precio Sin IVA
    HY-B0434-200mg
     200mg 
    HY-B0434-500mg
     500mg